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Abstract
Background: Agitation episodes are common among patients with schizophrenia or bipolar disorder. Oral and
intramuscular administration methods are commonly used in pharmacological treatment of acute agitation. Recently, an
innovative inhalation product with loxapine(Adasuve®)has become available for treatment of acute agitation episodes
associated with bipolar disorder or schizophrenia. The objective for the present study was to investigate the impact of
the pharmacological treatment’s administration methods on the health-related quality of life (HRQoL) in patients with
bipolar disorder or schizophrenia in Denmark and Sweden using a time trade-off (TTO) approach.
Methods: The TTO methodology was used to examine the HRQoL impact of administration method of
pharmacological treatment of acute agitation. Data were collected via an internet-based survey, using an
existing panel of respondents with schizophrenia or bipolar disorder.
Results: Respondents considered living with schizophrenia/ bipolar disorder, having one yearly agitation episode
treated with inhaler better than living with the same conditions and receiving treatment with tablet or injection. The
utility value was 0.762 for inhalable treatment, 0.707 for injection and 0.734 for tablet treatment.
Conclusions: Patients’ preference for treatment delivery options showed that inhalation was associated with a
significant utility gain when compared to injection or tablets. Inhalable loxapine may be a new tool for control
of agitation episodes for strengthening the patient provider alliance when taking patient’s preference for delivery
method into consideration.
Background
Agitation episodes are common among patients with
schizophrenia or bipolar disorder [1, 2]. Agitation is a
state where patients experience extreme alertness accom-
panied by restlessness and unorganized psychomotor
activity. Inadequate or late control of acute episodes of
agitation could drive escalation of symptoms to violent or
aggressive behaviors and might have a significant impact
on resource use and on patients’ lives [2]. Treatment of
moderate or severe acute agitation is normally managed
in hospital setting and includes both non-pharmacological
and pharmacological interventions. Currently, there is a
very strong focus in the Nordic countries on avoiding
coercive treatment and restraints in the psychiatric wards-
Initially, non-pharmacological methods of behaviour
control, such as a verbal intervention or de-escalation
techniques, may be helpful to manage agitated patients.
When initial non-pharmacological methods fail to calm
the patient, seclusion and/or physical restraint might be
appropriate, or there may be a need to initiate pharma-
cological interventions. The available medical treat-
ments for agitation include first- and second-generation
antipsychotics and benzodiazepines, and three routes of
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administration are possible: Oral/oral fast-dissolving
tablets, intramuscular, or intravenous [3]. Intravenous
administration of antipsychotic drugs offers a rapid
onset of action, but it is often impractical unless intra-
venous access is already established. As a result, oral
and intramuscular administrations are more commonly
used, but these routes entail a notably delayed onset of
action. A non-coercive, collaborative approach to man-
age agitation is recommended, and oral antipsychotics
are preferred in these collaborative interventions [4, 5].
Oral formulations may, however, sometimes be inappro-
priate due to the slow onset of action, which leaves a sig-
nificant period during which patients, staff and property
remain vulnerable to the deleterious behaviors associated
with agitation [6]. The use of intramuscular injections
may be limited by several barriers: Mental and physical
trauma to the patient, risk of compromising the patient-
physician relationship, exposure to contaminated needles
and negative effects on long-term compliance [6]. It has
been demonstrated that the subjective feeling after the
first medication is essential for the acceptance of medica-
tion and the further course of the episode [7].
According to ‘The Expert Consensus Guidelines for
Treatment of Behavioral Emergencies’, speed of onset, con-
trol of aggressive behavior, patient preference, long-term
physician-patient relationship and medication reliability of
delivery are identified as attributes for an anti-agitation
pharmacological treatment, of which speed of onset is con-
sidered as most important by the expert panel [6].
The route of administration is known to have great
impact on the time of onset and the elimination time of
the drug. Recently, a new product with inhalation as
delivery method has become available for treatment of
acute agitation episodes associated with bipolar dis-
order or schizophrenia. Inhalable loxapine (Adasuve®)
utilizes an antipsychotic used in psychiatry for 30 years
with a well-established efficacy and safety profile [8].
Adasuve® is a single-dose inhaler that dispenses a low
dose of loxapine (9.1 mg) directly into the lung tissue
for rapid absorption with a mean time of maximum
plasma concentration (Tmax) of 2 min, hence fast re-
lief for patients during an agitation episode [8–11].
The drug-delivery system is extensively described else-
where [12, 13].
In Denmark and Sweden, the standard medical treat-
ments of agitation episodes include antipsychotics admin-
istered per oral/oral or by intramuscular injections. The
efficacy of these is assumed to be comparable [14–16]. It is
known from other therapy areas (e.g., oncology and
diabetes) that patients prefer to receive the medication in
the form of tablets or an inhaled preparation rather than
as injections [17–19]. Oral or inhaled medications are also
associated with heightened levels of patient satisfaction
with their treatment [17, 20]. In Denmark the national
Council for the Use of Expensive Hospital Medicines
(RADS) guidelines and in Sweden the local “Wise Drug
Formulary” guidelines are used with the aim of choosing
the most suitable drug from an economical perspective,
with the flexibility of choosing more expensive drugs if
there is appropriate arguments in the patients’ files. In
the current study, the time trade-off (TTO) method-
ology was used to examine the impact of administration
method of pharmacological treatment of acute agitation
on the health-related quality of life (HRQoL). The TTO
method is recognized by the Health Technology Assess-
ment agencies for direct health-state valuation and is
used to calculate quality-adjusted life years (QALYs),
and for cost-effectiveness calculations of treatments.
The objective for the present study was to investigate
the impact of the administration method, in connection
with medical treatment of acute agitation, on health re-
lated quality of life (HRQoL) in patients with bipolar
disorder or schizophrenia in Denmark and Sweden
using a TTO approach.
Methods
Study design
The TTO method is a tool for eliciting utility values by
asking respondents to ‘trade off ’ a part of their remaining
lifespan to live in an improved health state. The TTO
method is described extensively elsewhere [21–29]. The
time horizon used in the questionnaire was based on each
respondent’s life expectancy. This was obtained by com-
bining information on the country, age and sex of the
respondents at the time of study and the most recent life
tables from the World Health Organization [30]. Respon-
dents were asked questions repeatedly, varying only the
remaining years in full health in order to identify an inter-
val around the point of indifference between the two
hypothetical health states (where both options are equally
acceptable). This procedure followed a standard bisection
methodology, using a starting point of utility 0.6 and from
there narrowing down the respondents’ interval around
the point of indifference by presenting them with 4–5
trade-offs. The distribution tails were given particular
attention. If respondents chose to trade a very high pro-
portion of their remaining lifespan or chose not to trade
any lifetime at all, their reasons for choosing so were
carefully screened.
Definition of health states
Health states were defined on the basis of patient expe-
riences derived from focus groups, from applicable
product summaries (SmPCs) from the European Medi-
cines Agency and by consulting a Danish medical expert.
Three health states were developed to elicit utility values
of 3 treatment methods for agitation episodes (Table 1).
The health states were described as involving ‘Injection’,
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‘Tablets’ and ‘Inhaler’. All health states were hypothetical,
and the respondents were asked to imagine that they lived
with schizophrenia or bipolar disorder and that they had
one yearly agitation episode (’schizophrenia’ or’bipolar dis-
order’ was displayed, depending on the respondent’s con-
dition). The only difference between the three health
states was the type of treatment of the agitation episode.
No brand names were presented in the questionnaire. For
the health state including tablet or injection as treatment,
olanzapine was chosen as a proxy, and inhalable loxapine
was used as a proxy for the health state including inhal-
ation as treatment of a yearly agitation episode. The
respective Tmax was used as the time to onset of efficacy
of inhalation and injection treatments. Intramuscular
injection with olanzapine has a Tmax of 15–45 min, and in
the questionnaire the time to efficacy was set to 30 min
[31]. The time to efficacy for inhalation was set to 2 min
(Tmax for inhalable loxapine) [11]. The tablet formulation
of olanzapine has a Tmax of 3–6 h [31], but time to onset
for oral formulations is reported as being earlier in the
literature [32]. As a consequence, and to make the health
states easier to compare and understand for patients, the
time to effect for tablets was described as 1 h.
Only adverse reactions stated as very common and
severe according to the respective SmPC were consid-
ered as relevant for the TTO methodology. As this study
concerned treatment of acute agitation only, sedation
was the only adverse reaction evaluated as applicable for
the TTO methodology. Clinical studies have shown that
approximately 30 % of patients receiving olanzapine
administered by oral or intramuscular route will experi-
ence sedation as measured on the Agitation-Calmness
Evaluation Scale (ACES = 7, 8 or 9) [31]. This adverse
reaction may be experienced for at least 24 h after the
treatment [33]. The half-life (T1/2) of olanzapine is 33 h,
and at this time it is expected that the risk of sedation is
no longer present. Yet it is not known from clinical
studies if sedation continues after 24 h. Approximately
10 % of patients receiving inhalable loxapine will
experience sedation [10]. In the health states describing
tablet or injection as treatment for agitation, the respon-
dents received the information that 1/3 will experience
sedation for 24 h. The half-life of inhalable loxapine
(Adasuve®) is 6–8 h, and no information is available on
whether patients experience sedation beyond this point.
In the questionnaire, it was stated that 1/10 of the
patients will experience sedation for 7 h when treated
with inhalation (Table 1).
Questionnaire design
Focus group interviews with 11 patients with bipolar dis-
order and 3 patients with schizophrenia, together with
their primary caregiver were conducted as a preparation
for the current survey. The focus group discussions gave
insights into how patients experience an agitation episode
as well as their experiences with adverse reactions of the
treatments. In the focus group, agitation was described by
the patients as feeling like restlessness, anger, anxiety or
impatience, hence a list of these words was used to de-
scribe the agitation in the questionnaire. The objective of
including caregivers was to gain insight into the caregivers’
experience of supporting patients living with acute agita-
tion and to discover the treatment characteristics most
valued by patients and their caregivers.
During the discussions, patients mentioned that
sedation in relation to medication for agitation felt like
grogginess or a hangover effect. The medical expert
consulted prior to conducting the current survey stated
that patients describe a ‘bubble feeling’. In order to use
patient terminology in the questionnaire, sedation was
described as feeling ‘sluggish, tired, having the bubble
feeling or feeling groggy’. The focus groups provided
background insight tat informed for development of the
survey questionnaire.
Survey description
Data were collected via an internet-based survey, using an
existing email panel of respondents who had previously




Injection You say yes to medication and receive the medication as an injection. It takes approximately 30 min for the medication to work. During the
period until the medication starts to work you are still exasperated, aggressive, restless, agitated or anxious. For approximately 1 day after you
have taken the medication, in 1 out of 3 cases you risk feeling sluggish, feeling tired, having the bubble feeling or feeling groggy.
Inhalation You say yes to the medication and receive the medication via an inhaler, which you use by exhaling, placing the inhaler in your mouth
and inhaling, whereby you receive the medication. It takes approximately 2 min for the medication to work. During the period until the
medication starts to work you are still exasperated, aggressive, restless, agitated or anxious. For approximately 7 h after you have taken
the medication, in 1 out of 10 cases you risk feeling sluggish, feeling tired, having the bubble feeling or feeling groggy.
Tablet You say yes to the medication and receive it in tablet form, which you swallow with a glass of water. It takes approximately 1 h for the medication
to work. During the period until the medication starts to work you are still exasperated, agitated or anxious. For approximately 1 day after you
have taken the medication, in 1 out of 3 cases you risk feeling sluggish, feeling tired, having the bubble feeling or feeling groggy.
Three health states (‘Injection’, ‘Tablets’ and ‘Inhaler’) were developed for eliciting utility values of 3 treatment methods for agitation episodes. All health states
included living with schizophrenia or bipolar disorder and having one yearly agitation episode. It was assumed that patients knew what it was like to live with
their own condition (schizophrenia or bipolar disorder), thus the questionnaire did not describe that. TTO = Time trade-off
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agreed to participate in internet-based surveys. The re-
spondents were anonymous and no sensitive information
such as names or addresses were known to the authors.
Inclusion criteria were consent to participate in the
survey, a self-reported diagnosis of either schizophrenia or
bipolar disorder and age above 18 years. The survey was
conducted in Denmark and Sweden from 30 October
2014 to 12 December 2014 and in Danish and Swedish,
respectively. The respondents received a remuneration
(1 €) for participating in the survey. The questionnaire
was programmed in a commercial survey software
package, SurveyXact®. To improve answer quality and
prevent unconsidered responses, a delay of 10 s was in-
troduced to pages with a large amount of text. The
functionality of the questionnaire was tested in a pilot
study of 12 respondents.
Exclusion criteria
Respondents were excluded if they refused to trade
on ethical or religious grounds or if they stated they
did not understand the question. On the other hand,
if respondents believed the health state was manage-
able or if they expressed a desire to live as long as
possible due to obligations (such as being a care-
giver), their answers were kept in the further analyses.
A test question was included to check the respon-
dents’ understanding of the TTO concept. In this
question, the respondents had to choose between 1)
full health and a longer remaining lifespan and 2) a
less than full health and a reduced lifetime. If respon-
dents chose the second option, they were excluded
from the TTO analysis.
Statistical analysis
Statistical analyses were performed in SAS® version 9.4
statistical software. Based on patients’ trade-offs, a utility
value was assigned to each of the three health states for all
respondents. This value was calculated as the midpoint of
the highest and the lowest utility values that the respon-
dents stated for a specific health state. For example, if
respondents answered that they had a utility higher than
0.80 and lower than 0.85, their utility was estimated to be
0.825. The average utility value was calculated for each
health state, and subsequently the difference in utility
between the different health states was calculated. The
response distribution was non-normal, so we used non-
parametric bootstrapping to simulate standard errors and
confidence intervals (CIs) for the mean TTO values. When
using this method, the parameter’s distribution is estimated
by repeatedly resampling the original data set with replace-




The number of eligible participants was 293 (176 with
bipolar disorder and 61 with schizophrenia), of which 56
(19 %) did not complete the questionnaire, 49 (17 %)
failed the TTO test question, and 20 (7 %) were excluded
from analysis as they traded too much or too little on
invalid grounds (such as religious or ethical grounds, or
if they did not understand the questions) (Fig. 1). There-
fore, 168 (57 %) respondents were included in the final
analysis. The demographic characteristics of the final
sample of respondents are summarized in Table 2.
Completed respondents: 237 (81%)
Failed test question: 49 (17%)
Invalid trading grounds: 20 (7%)
Valid respondents for TTO analysis: 168 (57%)
Respondents in the target group: 293
Partly complete: 56 (19%)
Fig. 1 Patient consort flow diagram. TTO: Time Trade-Off
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In total, there was a majority of female respondents
(67 %); however, respondents with schizophrenia were
more equally distributed with 51 % female respondents.
The average age of the respondents was 40 years, and
average age when diagnosed with their condition was
29 years. More respondents with schizophrenia had been
hospitalized, of which 41 % were hospitalized within the
last year. Among the respondents with bipolar disorder,
24 % had been hospitalized within the last year. Ninety
per cent of the respondents had experienced an agitation
episode. When patients themselves asked for medication
during an agitation episode, most patients (85 %) asked for
tablets. Among those patients who were given medication
against their will during an agitation episode, 52 % of
patients received injections and 29 % received tablets.
Nineteen per cent received both injections and tablets.
Eighty-one per cent of patients have experienced sedation
when receiving medical treatment.
TTO results
Figure 2 shows the utility of living with schizophrenia/
bipolar disorder and having one yearly agitation episode
for the 3 health states explored. Respondents considered
living with schizophrenia/bipolar disorder, and having
one yearly agitation episode treated with inhaler better
than living with the same conditions and receiving
treatment with tablets or injection. The utility value was
0.762 for inhalable treatment, 0.707 for injection and
0.734 for tablet treatment (Fig. 2). The differences in
utility between the treatments are seen in Fig. 3. The
utility difference between the injection and the inhaler
treatment is 0.044, and the difference in utility between
the tablet and the inhaler treatment was 0.019. The
utility difference between injection and inhaler treatment
and between tablets and inhaler are significantly different
at a 95 % CI as denoted by the error bars in Fig. 3. This
shows that patients gain a higher utility by receiving inhal-
able treatment compared with using injections or tablets.
Table 2 Demographic characteristic of the final sample
All Schizophrenia Bipolar disorder
N 168 41 127
Male (%) 33 51 27
Female (%) 67 49 73
Average age (years) 40 34 42
Average age at diagnosis (years) 29 22 32
Have been hospitalized (%) 64 85 57





























Fig. 2 QALY value for the different health states. Respondents considered living with schizophrenia/bipolar disorder and having one yearly
agitation episode treated with inhaler better than living with the same conditions and receiving treatment with tablets or injection. The utility
value was 0.762 for inhalable treatment, 0.707 for injection and 0.734 for tablet treatment. QALY: Quality-adjusted life years
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Discussion
This is the first study measuring patients’ self-reported
utilities associated with different routes of medicine
administration for control of agitation episodes using the
TTO method. Agitation episodes are common among
patients with schizophrenia or bipolar disorder; 90 % of
the respondents in this survey had experienced at least 1
agitation episode. The majority of the respondents in this
study had received intramuscular injection against their
will; 52 % had received injection, and 19 % had received
tablet and injection concomitantly against their will. A
desirable goal of using medication for agitation is to calm
the patient without inducing sleep, as it allows a patient-
provider alliance in the creation of a crisis management
plan. A recent consensus statement of the psycho-
pharmacology workgroup of the American Association
for Emergency Psychiatry recommends that patients
should be involved, if possible, in both the selection of
the type and the route of administration of any medication
[3]. Inhalation offers an alternative route of delivery for
pharmacological treatment of agitation episodes associated
with bipolar disorder or schizophrenia. The absorption site
and the lack of first-pass metabolism make the inhaled
form of medication the one to offer the fastest onset of
action, but it also requires some cooperation from the
patient. In the current study, patients reported inhalation
as the preferred administration method, as it was traded as
the most valuable treatment, indicated by the highest
QALY (Fig. 2). This indicates that patients might be willing
and cooperative to receive treatment delivered by
inhalation. Respondents traded injection as the least
valuable route of administration, indicated by the
lowest QALY (Fig. 2). Similar findings were found by
Atkinson et al., who demonstrated significant differ-
ences in satisfaction levels by route of medication
administration (oral, injectable, inhalable) across differ-
ent diseases. Injectable was the least preferred route of
administration regardless of disease [20].
As mentioned, this is the first study to elicit stated
preferences for the administration method of medication
for acute agitation in the form of health state preference
value. These values, taking the form of a single index on
a zero-to-one scale representing death and perfect
health, respectively, may be used as preference weights
in future economic evaluations. A UK study, including
stable outpatients with schizophrenia and no side effects
of treatment, obtained a utility value of 0.919, slightly
higher than in the current study [37]. This is not
surprising, as the current study included only 1 yearly
agitation episode. In the UK study, the side effect of
treatment lowered the utility value to 0.769, and extra-
pyramidal symptoms impaired the utility value to 0.722
[37]. In the current study, the utility value was 0.762 for
inhalable treatment and 0.707 for injection, which sup-
ports the theory that inhalable treatment for agitation
episodes would increase health utility in patients with
bipolar disorder or schizophrenia compared with current













Utility gain from injection to inhaler
N=159
Utility gain from tablet to inhaler
N=160
Fig. 3 QALY gain associated with change in treatment of 1 yearly agitation episode. The utility differences between injection and inhaler treatment
and between tablets and inhaler are significantly different at a 95 % CI as denoted by the error bars. QALY: Quality-adjusted life years
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may exceed the cost of treatment with tablets; however, the
preferences for inhaled administration may be sufficiently
strong among potential users of inhalable treatment to jus-
tify the additional cost. Poor management of agitation
among psychiatric patients can result in an inappropriate
use of coercive measures and/or escalation to patient
violence, both of which present a significant burden to
patients and caregivers as well as a substantial economic
burden to the healthcare system [2, 38]. This burden could
be substantially lowered by improved clinical management
of agitated patients, including the use of appropriate and
rapid interventions to avoid escalation to violence and
aggression.
The TTO instrument is relatively easy to use, which
makes it more appropriate to use in the current study
than the widely used standard gamble (SG) instrument as
SG can be difficult for respondents to understand [28]. To
use an age-dependent life-expectancy adaption of the
TTO questions is to increase the relevance compared with
the fixed 10- or 30-year trade-offs often used in other
studies. The repetitive nature of the TTO questions might
lead to fatigue among respondents. To avoid this, respon-
dents evaluated a limited number of health states and
were only given 4–5 iterative questions per health state
plus two follow-up questions to clarify extreme answers
(people who traded a lot or almost nothing). Because the
survey was web-based, it could be argued that it is biased
towards literate respondents with internet access and IT
competences. The literacy rate and IT competences are
generally very high in Sweden and Denmark, although
it is possibly somewhat lower in the target group of
this survey. The dropout rate of 19 % may seem high;
however, this is typical of web-based surveys used in
health-economic assessments [3–41]. The percentage
of patients who failed test questions or were excluded
on invalid trading grounds is also within limits of
comparable studies [42, 43].
A limitation of this study is the generalizability. Since
the study was conducted among a limited number of
patients in Denmark and Sweden, the results may not
be transferable to all patients in these countries or to
patients in other countries. We do, however, assume
that the results would reflect a preference observed in a
western health care context.
Conclusions
Agitation requires clinical intervention when the level of
hostility, excitement, uncooperativeness or lack of impulse
control is such that the potential exists for harm to self or
others. Currently tablets and injections are used to control
agitation episodes. Recently, a new rapidly acting inhal-
ation form of loxapine for acute agitation became available
for patients. This survey of patients’ preference for treat-
ment delivery options showed that patients preferred
inhalation as the delivery method. As a result, inhalation
was associated with a significant utility gain when com-
pared with injection or tablets. Inhalable loxapine might be
a new tool for control of agitation episodes that can be
used to strengthen the patient-provider alliance.
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